JP2011519950A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011519950A5 JP2011519950A5 JP2011508636A JP2011508636A JP2011519950A5 JP 2011519950 A5 JP2011519950 A5 JP 2011519950A5 JP 2011508636 A JP2011508636 A JP 2011508636A JP 2011508636 A JP2011508636 A JP 2011508636A JP 2011519950 A5 JP2011519950 A5 JP 2011519950A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- variant
- crig
- complement
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102220102892 rs878855278 Human genes 0.000 claims 21
- 239000003814 drug Substances 0.000 claims 10
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 102200058227 rs773814837 Human genes 0.000 claims 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 7
- 230000000295 complement effect Effects 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 7
- 238000006467 substitution reaction Methods 0.000 claims 7
- 206010064930 age-related macular degeneration Diseases 0.000 claims 5
- 208000002780 macular degeneration Diseases 0.000 claims 5
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 5
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 3
- 206010018364 Glomerulonephritis Diseases 0.000 claims 3
- 101000727061 Homo sapiens Complement receptor type 1 Proteins 0.000 claims 3
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 3
- 102000046508 human CR1 Human genes 0.000 claims 3
- 201000006417 multiple sclerosis Diseases 0.000 claims 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 2
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims 2
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 claims 2
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 claims 2
- 206010035664 Pneumonia Diseases 0.000 claims 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 2
- 206010046851 Uveitis Diseases 0.000 claims 2
- 206010047115 Vasculitis Diseases 0.000 claims 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 2
- 208000026935 allergic disease Diseases 0.000 claims 2
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 2
- 230000002612 cardiopulmonary effect Effects 0.000 claims 2
- 201000005667 central retinal vein occlusion Diseases 0.000 claims 2
- 201000001981 dermatomyositis Diseases 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 206010014801 endophthalmitis Diseases 0.000 claims 2
- 208000027993 eye symptom Diseases 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 208000028867 ischemia Diseases 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 claims 2
- 230000037361 pathway Effects 0.000 claims 2
- 230000003389 potentiating effect Effects 0.000 claims 2
- 208000004644 retinal vein occlusion Diseases 0.000 claims 2
- 102200071151 rs137853184 Human genes 0.000 claims 2
- 208000009304 Acute Kidney Injury Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims 1
- 102220609081 Apolipoprotein E_Q99K_mutation Human genes 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 1
- 206010050245 Autoimmune thrombocytopenia Diseases 0.000 claims 1
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 108010078015 Complement C3b Proteins 0.000 claims 1
- 206010055665 Corneal neovascularisation Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 208000016192 Demyelinating disease Diseases 0.000 claims 1
- 206010012442 Dermatitis contact Diseases 0.000 claims 1
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims 1
- 201000009273 Endometriosis Diseases 0.000 claims 1
- 206010048554 Endothelial dysfunction Diseases 0.000 claims 1
- 206010015150 Erythema Diseases 0.000 claims 1
- 208000004332 Evans syndrome Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 108010068370 Glutens Proteins 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 1
- 208000032759 Hemolytic-Uremic Syndrome Diseases 0.000 claims 1
- 208000037319 Hepatitis infectious Diseases 0.000 claims 1
- 206010019860 Hereditary angioedema Diseases 0.000 claims 1
- 201000002563 Histoplasmosis Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 1
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims 1
- 206010021263 IgA nephropathy Diseases 0.000 claims 1
- 208000028622 Immune thrombocytopenia Diseases 0.000 claims 1
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 208000005777 Lupus Nephritis Diseases 0.000 claims 1
- 201000005505 Measles Diseases 0.000 claims 1
- 208000004451 Membranoproliferative Glomerulonephritis Diseases 0.000 claims 1
- 201000002481 Myositis Diseases 0.000 claims 1
- 241000721454 Pemphigus Species 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000033626 Renal failure acute Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 208000007135 Retinal Neovascularization Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 208000006045 Spondylarthropathies Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 208000004732 Systemic Vasculitis Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 208000024780 Urticaria Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 208000027207 Whipple disease Diseases 0.000 claims 1
- 201000011040 acute kidney failure Diseases 0.000 claims 1
- 208000012998 acute renal failure Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000010927 atrophic thyroiditis Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 1
- 208000019748 bullous skin disease Diseases 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 230000024203 complement activation Effects 0.000 claims 1
- 208000010247 contact dermatitis Diseases 0.000 claims 1
- 201000000159 corneal neovascularization Diseases 0.000 claims 1
- 210000004351 coronary vessel Anatomy 0.000 claims 1
- 201000003278 cryoglobulinemia Diseases 0.000 claims 1
- 208000001309 degenerative myopia Diseases 0.000 claims 1
- 230000004340 degenerative myopia Effects 0.000 claims 1
- 201000011190 diabetic macular edema Diseases 0.000 claims 1
- 230000008694 endothelial dysfunction Effects 0.000 claims 1
- 201000009580 eosinophilic pneumonia Diseases 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 231100000321 erythema Toxicity 0.000 claims 1
- 230000003176 fibrotic effect Effects 0.000 claims 1
- 208000020694 gallbladder disease Diseases 0.000 claims 1
- 235000021312 gluten Nutrition 0.000 claims 1
- 201000007192 granulomatous hepatitis Diseases 0.000 claims 1
- 238000001631 haemodialysis Methods 0.000 claims 1
- 230000000322 hemodialysis Effects 0.000 claims 1
- 208000005252 hepatitis A Diseases 0.000 claims 1
- 201000010284 hepatitis E Diseases 0.000 claims 1
- 230000001553 hepatotropic effect Effects 0.000 claims 1
- 230000009610 hypersensitivity Effects 0.000 claims 1
- 208000013643 idiopathic inflammatory myopathy Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims 1
- 230000000366 juvenile effect Effects 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000008383 nephritis Diseases 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 210000001428 peripheral nervous system Anatomy 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000005987 polymyositis Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 201000009732 pulmonary eosinophilia Diseases 0.000 claims 1
- 230000010410 reperfusion Effects 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 208000010157 sclerosing cholangitis Diseases 0.000 claims 1
- 230000035939 shock Effects 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 201000005671 spondyloarthropathy Diseases 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 201000003067 thrombocytopenia due to platelet alloimmunization Diseases 0.000 claims 1
- 206010043778 thyroiditis Diseases 0.000 claims 1
- 230000000451 tissue damage Effects 0.000 claims 1
- 231100000827 tissue damage Toxicity 0.000 claims 1
- 208000006542 von Hippel-Lindau disease Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5088808P | 2008-05-06 | 2008-05-06 | |
| US61/050,888 | 2008-05-06 | ||
| US18965308P | 2008-08-20 | 2008-08-20 | |
| US61/189,653 | 2008-08-20 | ||
| PCT/US2009/043020 WO2009137605A2 (en) | 2008-05-06 | 2009-05-06 | AFFINITY MATURED CRIg VARIANTS |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015023559A Division JP2015145369A (ja) | 2008-05-06 | 2015-02-09 | 親和性成熟ＣＲＩｇ変異体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011519950A JP2011519950A (ja) | 2011-07-14 |
| JP2011519950A5 true JP2011519950A5 (https=) | 2013-03-07 |
| JP5836800B2 JP5836800B2 (ja) | 2015-12-24 |
Family
ID=41168511
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011508636A Expired - Fee Related JP5836800B2 (ja) | 2008-05-06 | 2009-05-06 | 親和性成熟ＣＲＩｇ変異体 |
| JP2015023559A Pending JP2015145369A (ja) | 2008-05-06 | 2015-02-09 | 親和性成熟ＣＲＩｇ変異体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015023559A Pending JP2015145369A (ja) | 2008-05-06 | 2015-02-09 | 親和性成熟ＣＲＩｇ変異体 |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US9234024B2 (https=) |
| EP (2) | EP2280996B1 (https=) |
| JP (2) | JP5836800B2 (https=) |
| KR (2) | KR101690590B1 (https=) |
| CN (2) | CN104558151A (https=) |
| AR (1) | AR071635A1 (https=) |
| AU (1) | AU2009244300B2 (https=) |
| BR (1) | BRPI0912003A2 (https=) |
| CA (1) | CA2720685C (https=) |
| CL (1) | CL2009001083A1 (https=) |
| CY (1) | CY1118240T1 (https=) |
| DK (1) | DK2280996T3 (https=) |
| ES (1) | ES2605471T3 (https=) |
| HK (1) | HK1210184A1 (https=) |
| HR (1) | HRP20161580T1 (https=) |
| HU (1) | HUE030092T2 (https=) |
| IL (2) | IL208379A (https=) |
| LT (1) | LT2280996T (https=) |
| MX (1) | MX2010011372A (https=) |
| PE (2) | PE20091923A1 (https=) |
| PL (1) | PL2280996T3 (https=) |
| PT (1) | PT2280996T (https=) |
| RU (2) | RU2015117054A (https=) |
| SG (1) | SG190596A1 (https=) |
| SI (1) | SI2280996T1 (https=) |
| TW (1) | TWI508973B (https=) |
| WO (1) | WO2009137605A2 (https=) |
| ZA (1) | ZA201006937B (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104231085B (zh) * | 2013-09-05 | 2017-03-15 | 复旦大学附属肿瘤医院 | 靶向特异性补体系统抑制剂、其制备方法及应用 |
| US11535655B2 (en) * | 2019-12-06 | 2022-12-27 | Cheer Global Limited | Method of treating inflammatory bowel disease |
| CN113583107B (zh) * | 2021-07-28 | 2023-11-10 | 复旦大学 | CRIg功能区蛋白变体及其应用 |
| WO2023080788A1 (en) * | 2021-11-05 | 2023-05-11 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Tryptophan depletion induces production and presentation of tryptophan to phenylalanine substitutions |
| EP4590697A2 (en) * | 2022-09-20 | 2025-07-30 | Visterra, Inc. | Treatment of complement mediated diseases and disorders with c3b-antibodies |
| TW202523706A (zh) * | 2023-11-13 | 2025-06-16 | 大陸商瀋陽三生製藥有限責任公司 | 一種靶向C3b的雙功能融合蛋白及其製備方法與用途 |
| CN118584103B (zh) * | 2024-07-05 | 2025-06-17 | 中国医科大学附属第一医院 | 中枢神经精神狼疮脑脊液诊断标志物及其应用 |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| US4579827A (en) | 1983-03-11 | 1986-04-01 | Sloan-Kettering Institute For Cancer Research | Monoclonal antibodies to human gastrointestinal cancers and hybridoma method of production of the monoclonal antibodies |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
| EP0199141A3 (en) | 1985-04-19 | 1988-07-20 | Sloan-Kettering Institute For Cancer Research | Monoclonal antibodies to human gastrointestinal cancer |
| GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
| US4973478A (en) | 1987-07-20 | 1990-11-27 | Allelix Biopharmaceuticals, Inc. | Treating inflammation with hepatocyte stimulating factor interferon β2 |
| ATE135397T1 (de) | 1988-09-23 | 1996-03-15 | Cetus Oncology Corp | Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte |
| WO1990005537A1 (en) | 1988-11-16 | 1990-05-31 | Brigham And Women's Hospital | Inhib, a factor which inhibits cytokine-activated leukocytes |
| US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
| GB8922987D0 (en) * | 1989-10-12 | 1989-11-29 | Imutran Ltd | Modified biological material |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| CA2095633C (en) | 1990-12-03 | 2003-02-04 | Lisa J. Garrard | Enrichment method for variant proteins with altered binding properties |
| PT616812E (pt) | 1993-03-24 | 2000-04-28 | Berlex Biosciences | Combinacao de compostos anti-hormonais e moleculas de ligacao no tratamento do cancro |
| US5650295A (en) | 1995-06-02 | 1997-07-22 | Human Genone Sciences, Inc. | Macrophage migration inhibitory factor-3 |
| WO2001004311A1 (en) | 1999-07-07 | 2001-01-18 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| AU706241B2 (en) | 1995-05-04 | 1999-06-10 | City Of Hope | Human leukocyte 12-lipoxygenase and its role in the pathogenesis of disease states |
| WO2002008284A2 (en) | 2000-07-20 | 2002-01-31 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
| WO2002000690A2 (en) | 2000-06-23 | 2002-01-03 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
| SE9604470D0 (sv) | 1996-12-04 | 1996-12-04 | Tamas Bartfai Konsulting Ab | Transmembrane component of tight junction |
| AU6552198A (en) | 1997-03-14 | 1998-09-29 | Human Genome Sciences, Inc. | 28 human secreted proteins |
| CA2283631A1 (en) | 1997-03-21 | 1998-10-01 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
| JP2001509372A (ja) | 1997-07-10 | 2001-07-24 | スミスクライン ビーチャム コーポレーション | 血小板凝集に関与する細胞表面受容体であるヒトｆ１１抗原 |
| US6410708B1 (en) | 1997-11-21 | 2002-06-25 | Genentech, Inc. | Nucleic acids encoding A-33 related antigen polypeptides |
| US7419663B2 (en) * | 1998-03-20 | 2008-09-02 | Genentech, Inc. | Treatment of complement-associated disorders |
| US8088386B2 (en) | 1998-03-20 | 2012-01-03 | Genentech, Inc. | Treatment of complement-associated disorders |
| US7192589B2 (en) | 1998-09-16 | 2007-03-20 | Genentech, Inc. | Treatment of inflammatory disorders with STIgMA immunoadhesins |
| ATE410512T1 (de) | 1997-11-21 | 2008-10-15 | Genentech Inc | Plättchen-spezifische antigene und deren pharmazeutische verwendung |
| US7282565B2 (en) | 1998-03-20 | 2007-10-16 | Genentech, Inc. | PRO362 polypeptides |
| AU2577799A (en) | 1998-02-09 | 1999-08-23 | Human Genome Sciences, Inc. | 45 human secreted proteins |
| US6022708A (en) | 1998-02-26 | 2000-02-08 | Genentech, Inc. | Fused |
| ES2312205T3 (es) | 1998-03-10 | 2009-02-16 | Genentech, Inc. | Nuevo polipeptido y acidos nucleicos que lo codifican. |
| AU5587799A (en) | 1998-08-27 | 2000-03-21 | Incyte Pharmaceuticals, Inc. | Protein transport-associated molecules |
| AU1631000A (en) | 1998-11-19 | 2000-06-05 | Incyte Pharmaceuticals, Inc. | Immunoglobulin superfamily proteins |
| CA2348757A1 (en) | 1998-12-16 | 2000-06-22 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| ES2327785T3 (es) | 1998-12-22 | 2009-11-03 | Genentech, Inc. | Procedimientos y compuestos para inhibir el crecimiento de celulas neoplasticas. |
| CA2362427A1 (en) | 1999-03-08 | 2000-09-14 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| EP1234030A4 (en) | 1999-11-19 | 2003-05-07 | Human Genome Sciences Inc | 18 HUMANE SECRETIED PROTEINS |
| CA2491433A1 (en) | 1999-12-01 | 2001-06-07 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| AU2003258714A1 (en) * | 2002-09-06 | 2004-03-29 | Cytos Biotechnology Ag | Immune modulatory compounds and methods |
| US7776573B2 (en) * | 2006-06-01 | 2010-08-17 | Genentech, Inc. | Crystal structure of CRIg and C3b:CRIg complex |
| JP2010505743A (ja) * | 2006-06-01 | 2010-02-25 | ジェネンテック インコーポレイテッド | ＣＲＩｇ及びＣ３ｂ：ＣＲＩｇ複合体の結晶構造 |
| US20090162356A1 (en) * | 2007-05-01 | 2009-06-25 | Menno Van Lookeren Campagne | CRIg antagonists |
-
2009
- 2009-05-06 SG SG2013032388A patent/SG190596A1/en unknown
- 2009-05-06 CA CA2720685A patent/CA2720685C/en not_active Expired - Fee Related
- 2009-05-06 WO PCT/US2009/043020 patent/WO2009137605A2/en not_active Ceased
- 2009-05-06 PT PT97435911T patent/PT2280996T/pt unknown
- 2009-05-06 PL PL09743591T patent/PL2280996T3/pl unknown
- 2009-05-06 US US12/387,794 patent/US9234024B2/en not_active Expired - Fee Related
- 2009-05-06 AR ARP090101632A patent/AR071635A1/es unknown
- 2009-05-06 PE PE2009000626A patent/PE20091923A1/es not_active Application Discontinuation
- 2009-05-06 CL CL2009001083A patent/CL2009001083A1/es unknown
- 2009-05-06 TW TW098115004A patent/TWI508973B/zh not_active IP Right Cessation
- 2009-05-06 JP JP2011508636A patent/JP5836800B2/ja not_active Expired - Fee Related
- 2009-05-06 KR KR1020107027276A patent/KR101690590B1/ko not_active Expired - Fee Related
- 2009-05-06 HR HRP20161580TT patent/HRP20161580T1/hr unknown
- 2009-05-06 CN CN201410686051.4A patent/CN104558151A/zh active Pending
- 2009-05-06 BR BRPI0912003A patent/BRPI0912003A2/pt not_active IP Right Cessation
- 2009-05-06 EP EP09743591.1A patent/EP2280996B1/en active Active
- 2009-05-06 PE PE2014000442A patent/PE20141549A1/es not_active Application Discontinuation
- 2009-05-06 MX MX2010011372A patent/MX2010011372A/es active IP Right Grant
- 2009-05-06 RU RU2015117054/10A patent/RU2015117054A/ru not_active Application Discontinuation
- 2009-05-06 LT LTEP09743591.1T patent/LT2280996T/lt unknown
- 2009-05-06 RU RU2010149804/10A patent/RU2553517C2/ru not_active IP Right Cessation
- 2009-05-06 AU AU2009244300A patent/AU2009244300B2/en not_active Ceased
- 2009-05-06 ES ES09743591.1T patent/ES2605471T3/es active Active
- 2009-05-06 DK DK09743591.1T patent/DK2280996T3/en active
- 2009-05-06 EP EP16173577.4A patent/EP3141560A3/en not_active Withdrawn
- 2009-05-06 CN CN200980116490.9A patent/CN102015763B/zh not_active Expired - Fee Related
- 2009-05-06 SI SI200931567A patent/SI2280996T1/sl unknown
- 2009-05-06 HU HUE09743591A patent/HUE030092T2/en unknown
- 2009-05-06 KR KR1020167035910A patent/KR20170001711A/ko not_active Ceased
-
2010
- 2010-09-29 ZA ZA2010/06937A patent/ZA201006937B/en unknown
- 2010-10-03 IL IL208379A patent/IL208379A/en not_active IP Right Cessation
-
2015
- 2015-02-09 JP JP2015023559A patent/JP2015145369A/ja active Pending
- 2015-04-20 US US14/690,891 patent/US20160008427A1/en not_active Abandoned
- 2015-10-29 HK HK15110724.5A patent/HK1210184A1/xx unknown
-
2016
- 2016-11-17 CY CY20161101186T patent/CY1118240T1/el unknown
- 2016-12-11 IL IL249492A patent/IL249492A0/en unknown